Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing burden of anthrax globally
3.2.1.2 Technology advancements in the vaccine development
3.2.1.3 Increased globalization and travel
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness for diagnostic test of target disease
3.2.2.2 High cost of vaccine
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Cell free PA vaccine
5.2.1 Anthrax vaccine absorbed (AVA)
5.2.2 Anthrax vaccine precipitated (AVP)
5.3 Live attenuated vaccine
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Veterinary use
6.3 Human use
Chapter 7 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Veterinary hospitals & clinics
7.3 Hospital & clinics
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Altimmune Inc.
9.2 Agrovet
9.3 Bayer AG
9.4 Bavarian Nordic
9.5 Biogenesis Bago SA
9.6 Ceva Sante Animale
9.7 Colondo Serum Company
9.8 Emergent BioSolutions
9.9 Elusys Therapeutics Inc.
9.10 Indian Immunologicals Ltd.
9.11 Intervac (PVT) Ltd
9.12 JOVAC
9.13 Merck Co, Inc.
9.14 Proton Biopharma Ltd.
